Thus, we investigated longitudinal serum IGF-1 data of HC and PD patients for differences at baseline, annual changes in IGF-1, and annual changes in clinical measures of PD in relationship to baseline IGF-1. This evidence concerns the gene IGF1 and Parkinson disease.